ÂÜÀòÂÒÂ×

Dr. Muntañola holds a PhD in Molecular Biology from the University of Navarra (Navarra, Spain) and an MBA from ESADE Business School (Barcelona, Spain).

He began his career at Werfen Group (In Vitro Diagnostics) assuming various national and international R&D and tech transfer roles, including three years in the United States developing a new molecular diagnostic technology to detect DNA mutations. After eight years at Werfen, he joined ESTEVE in 2010 to support R&D Strategic Marketing, and then added responsibilities in Licensing and Corporate Strategy. In 2013, he moved to Esaote (Medical Imaging Technology), a private equity backed Italian company as Director of Corporate Development (in charge of Business Development, Strategy and M&A) where he stayed for 3 years as member of the new management team to lead the transformation journey and turn around. While at Esaote, he was also appointed as a member of the Board of Directors of Elesta, a JV company within Esaote focused on developing minimally invasive procedures to treat tumors based on laser ablation therapy. He re-joined ESTEVE in 2016 as Director of Operational Excellence (both commercial and operational), and then assumed responsibilities as Director of Consumer Care Business and Head of Transformation Office.

He was appointed Chief Commercial Officer of the pharmaceutical activity in February 2019.